Drug Profile
Cefepime/taniborbactam - VenatoRx Pharmaceuticals
Alternative Names: Cefepime/VNRX-5133; VNRX-5133/VNRX-5022; VNRX5133/CefepimeLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator VenatoRx Pharmaceuticals
- Developer Everest Medicines; National Institute of Allergy and Infectious Diseases; VenatoRx Pharmaceuticals
- Class Anti-inflammatories; Antibacterials; Beta-lactams; Cephalosporins; Small molecules
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Pyelonephritis; Urinary tract infections
- No development reported Bacterial infections
Most Recent Events
- 23 Feb 2024 Melinta Therapeutics announces intention to launch Cefepme/taniborbactam for Urinary tract infections in USA
- 23 Feb 2024 Melinta Therapeutics receives complete response letter from the US FDA for Cefepime/taniborbactam in Urinary tract infections
- 09 Jan 2024 Menarini and Venatorx Pharmaceuticals enter into a Licensing agreement for Cefepime/Taniborbactam